Taiko Pharmaceutical Co.,Ltd. (4574.T)
JPY 322.0
(0.0%)
JPY 322.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -3.75 Billion JPY | 32.65% |
| 2021 | -5.56 Billion JPY | -194.0% |
| 2020 | 5.92 Billion JPY | 45.68% |
| 2019 | 4.06 Billion JPY | 70.13% |
| 2018 | 2.38 Billion JPY | 2.75% |
| 2017 | 2.32 Billion JPY | 21.97% |
| 2016 | 1.9 Billion JPY | 14.81% |
| 2015 | 1.66 Billion JPY | -41.88% |
| 2014 | 2.85 Billion JPY | -4.09% |
| 2013 | 2.97 Billion JPY | 100.96% |
| 2012 | 1.48 Billion JPY | 61.46% |
| 2011 | 918.23 Million JPY | 564.37% |
| 2010 | -197.73 Million JPY | -107.48% |
| 2009 | 2.64 Billion JPY | 116.08% |
| 2008 | 1.22 Billion JPY | 46.84% |
| 2007 | 833.25 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -79 Million JPY | 70.3% |
| 2023 Q2 | -266 Million JPY | -10.83% |
| 2023 Q1 | -240 Million JPY | 84.71% |
| 2022 Q3 | -401 Million JPY | 47.92% |
| 2022 FY | - JPY | 32.65% |
| 2022 Q4 | -1.57 Billion JPY | -291.52% |
| 2022 Q1 | -1.74 Billion JPY | 57.66% |
| 2022 Q2 | -770 Million JPY | 55.9% |
| 2021 Q1 | -191 Million JPY | 0.0% |
| 2021 Q2 | -2.7 Billion JPY | -1318.32% |
| 2021 FY | - JPY | -194.0% |
| 2021 Q4 | -4.12 Billion JPY | -1278.29% |
| 2021 Q3 | 350 Million JPY | 112.92% |
| 2020 FY | - JPY | 45.68% |
| 2020 Q1 | 437.36 Million JPY | -79.98% |
| 2020 Q3 | 1.4 Billion JPY | -47.85% |
| 2020 Q2 | 2.7 Billion JPY | 517.95% |
| 2019 Q2 | 127.47 Million JPY | 200.93% |
| 2019 FY | - JPY | 70.13% |
| 2019 Q1 | 42.36 Million JPY | -96.62% |
| 2019 Q3 | 755.18 Million JPY | 492.4% |
| 2019 Q4 | 2.18 Billion JPY | 189.29% |
| 2018 Q4 | 1.25 Billion JPY | 115.42% |
| 2018 Q3 | 581.96 Million JPY | 1041.01% |
| 2018 Q1 | -25.5 Million JPY | -101.8% |
| 2018 Q2 | 51 Million JPY | 299.99% |
| 2018 FY | - JPY | 2.75% |
| 2017 Q3 | 321.3 Million JPY | 98.02% |
| 2017 Q2 | 162.25 Million JPY | 197.57% |
| 2017 Q1 | -166.3 Million JPY | -114.03% |
| 2017 FY | - JPY | 21.97% |
| 2017 Q4 | 1.41 Billion JPY | 340.14% |
| 2016 Q4 | 1.18 Billion JPY | 151.04% |
| 2016 FY | - JPY | 14.81% |
| 2016 Q3 | 472.15 Million JPY | 1721.41% |
| 2016 Q2 | -29.12 Million JPY | -186.73% |
| 2016 Q1 | -10.15 Million JPY | -101.11% |
| 2015 Q2 | 204.13 Million JPY | 92.11% |
| 2015 Q1 | 106.25 Million JPY | -92.92% |
| 2015 Q4 | 914.42 Million JPY | 352.87% |
| 2015 FY | - JPY | -41.88% |
| 2015 Q3 | 201.91 Million JPY | -1.09% |
| 2014 Q4 | 1.5 Billion JPY | 170.39% |
| 2014 Q3 | 555.19 Million JPY | 34.01% |
| 2014 Q1 | 108.7 Million JPY | -90.76% |
| 2014 Q2 | 414.29 Million JPY | 281.13% |
| 2014 FY | - JPY | -4.09% |
| 2013 Q1 | -62.23 Million JPY | -108.35% |
| 2013 FY | - JPY | 100.96% |
| 2013 Q2 | 622.11 Million JPY | 1099.57% |
| 2013 Q4 | 1.17 Billion JPY | 43.92% |
| 2013 Q3 | 817.55 Million JPY | 31.42% |
| 2012 Q4 | 745.55 Million JPY | 147.55% |
| 2012 Q2 | 247.58 Million JPY | 178.95% |
| 2012 FY | - JPY | 61.46% |
| 2012 Q1 | -313.61 Million JPY | -210.2% |
| 2012 Q3 | 301.17 Million JPY | 21.64% |
| 2011 Q3 | 438.27 Million JPY | 75.21% |
| 2011 Q2 | 250.14 Million JPY | 1177.37% |
| 2011 FY | - JPY | 564.37% |
| 2011 Q1 | 19.58 Million JPY | 119.08% |
| 2011 Q4 | 284.58 Million JPY | -35.07% |
| 2010 Q3 | 56.68 Million JPY | 133.08% |
| 2010 Q1 | -527.35 Million JPY | -141.93% |
| 2010 Q4 | -102.63 Million JPY | -281.06% |
| 2010 FY | - JPY | -107.48% |
| 2010 Q2 | -171.37 Million JPY | 67.5% |
| 2009 Q4 | 1.25 Billion JPY | 9.35% |
| 2009 Q3 | 1.15 Billion JPY | 50.73% |
| 2009 Q2 | 763.13 Million JPY | 476.19% |
| 2009 Q1 | 132.44 Million JPY | -79.78% |
| 2009 FY | - JPY | 116.08% |
| 2008 FY | - JPY | 46.84% |
| 2008 Q4 | 654.92 Million JPY | 0.0% |
| 2007 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 162.282% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 100.429% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 98.666% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 102.009% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | 756.775% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 110.333% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 130.57% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 103.637% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | 390.023% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 120.447% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 141.792% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 202.18% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | 367.284% |
| Tsumura & Co. | 30.77 Billion JPY | 112.186% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 120.032% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 171.144% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 110.553% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 154.49% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 121.402% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 136.422% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 149.649% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | -425.21% |
| MedRx Co., Ltd | -884.51 Million JPY | -323.961% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 167.735% |
| Solasia Pharma K.K. | -635 Million JPY | -490.551% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | -57.966% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 140.925% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 110.17% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | -596.652% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 114.51% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 173.506% |